In this edition of Device Week, Medtech Insight's deputy editor Reed Miller chats with managing editor Marion Webb about her latest in-depth Market Intel story, the first part of a two-part series focusing on the competitive landscape of the global insulin pump market.

ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.

ConMed Corp. is company of two halves  ̶  general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.

The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings. 

The insulin pump market is expected to grow to $5.1bn by 2023, driven by the increasing incidence of diabetes and adoption of next-generation hybrid closed-loop systems, which allow patients and health-care providers to better manage care. This first part of a two-part series highlights the rising competitive landscape of the four major players, Medtronic, Insulet, Tandem Diabetes Care and Valeritas, with insights from endocrinologists. The second part will look at the smaller players, which are gearing up to introduce new products in 2020.

CMR Surgical CEO Martin Frost is making way for a new boss to lead the surgical robotics company. Per Vegard Nerseth is set to join CMR Surgical in January 2020 as the company gears up for its most ambitious year yet.

Medical device regulations that were set in place by the US FDA in the 1990s are evolving with the emergence of digital-health products and their iterative nature, medtech consultant Jon Speer says. Check out his comment here.

Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.

Koa Accel CEO Francis Duhay outlines his company’s plans to take some of the risk out of investing in medical device start-ups by supporting inventors with functional expertise. The Irvine, CA-based medical device accelerator is focused on start-ups that will either “fail fast” or earn a 510(k) clearance within 18 months.